• Giuseppe Del Giudice, Anne Katrin Hilbert, Roberto Bugarini, Ada Minutello, Olga Popova, Daniela Toneatto, Ines Schoendorf, Astrid Borkowski, Rino Rappuoli, and Audino Podda.
• Chiron Vaccines, Research Center and Clinical Research, Via Fiorentina 1, 53100 Siena, Italy. giuseppe.del.giudice@chiron.com
• Vaccine. 2006 Apr 12; 24 (16): 3063-5.

AbstractTo test whether inactivated influenza vaccines distributed during the 2003-2004 influenza season in the northern hemisphere were able to confer protection against the mismatched variant A/Fujian/411/2002 virus strain, we measured haemagglutination inhibiting (HI) antibodies in elderly subjects vaccinated with three inactivated vaccines against the homologous A/H3N2 vaccine strain (A/Panama) and against the mismatched A/Fujian strain. The results showed that, while 76 to 80% of elder people vaccinated with conventional vaccines had protected levels of antibodies against the A/Fujian heterovariant strain, those vaccinated with the MF59-adjuvanted vaccine have protective levels of antibodies in >98% of the cases. We conclude that MF59-adjuvanted vaccines confer protection also against influenza virus strains which are not fully matched with those included in the vaccine.

28 keywords...

hide…